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This study was undertaken to verify whether simvastatin 
modulates Cav-1/eNOS expression, and if this modula-
tion is associated with changes in pro- and anti-inflam-
matory cytokine and Toll-like receptor 4 (TLR4) level in 
abdominal aortic aneurysm (AAA). It is a 1:2 case-control 
study of non-statin (n=12) and simvastatin-treated pa-
tients (n=24) who underwent open AAA repair. Simvas-
tatin treatment decreased Cav-1 (p<0.05) and increased 
eNOS expression (p<0.01) in the AAA wall. These chang-
es might be dose dependent. The changes in Cav-1 and 
eNOS were associated with a trend towards decreased 
IL-6 and IL-17 concentration (p>0.05) and increased IL-10 
concentration (p=0.055); however, TLR4 expression was 
unaffected, suggesting that simvastatin influences Cav-1 
and eNOS in the AAA wall by other mechanisms. Simv-
astatin may modulate Cav-1 and eNOS expression in the 
aneurysmal wall, indicating a potentially beneficial role 
for statins in AAA patients.
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INTRODUCTION
Abdominal aortic aneurysm (AAA) is defined as a dil-
atation of the aorta to a diameter greater than 50% of 
normal (Johnston et al., 1991); it typically occurs in the 
infrarenal aorta (Takayama & Yamanouchi, 2013) and in 
most cases is associated with atherosclerosis. A recent 
review of pharmaceutical treatments of AAA (Kokje et 
al., 2015) found that statins may have a beneficial ef-
fect. Statins are widely known to modulate the lipid pro-
file, but the recent discovery of their pleiotropic effects 
has triggered new lines of research which indicate they 
may also have beneficial applications in the treatment of 
AAAs (Mastoraki et al., 2012). Simvastatin, a commonly-
used statin, was shown to possess a substantial potential 
for modulating interleukins IL-4, IL-6, IL-10, and tumor 
necrosis factor TNF-α (Piechota-Polanczyk et al., 2012), 
as well as the matrix metalloproteinase MMP-9 (Evans et 
al., 2007) and nuclear factor kappa B (NF-κB) in AAAs 
(Piechota-Polanczyk et al., 2012). 
Endothelial nitric oxide synthase (eNOS) is the main 
producer of nitric oxide (NO) in the endothelium. Tur-
bulent flow conditions result in its uncoupling, triggering 
the endothelial cell dysfunctions observed in many car-
diovascular diseases (Huk et al., 1997; Kanai et al., 1995). 
Although elevated eNOS expression has a beneficial ef-
fect in the pathogenesis of AAA, its role seems to be 
more complex (Piechota-Polanczyk et al., 2015b). Under 
particular conditions, eNOS uncoupling might negatively 
correlate with the vasodilatory effect of NO and partici-
pate in AAA formation (Gao et al., 2012). In addition, 
the eNOS deficiency seen in atherosclerosis has been 
found to cause spontaneous aortic aneurysms in ApoE 
knock-out mice (Kuhlencordt et al., 2001).  
Caveolin-1 (Cav-1) is a structural protein of the cave-
olae known to possess a functional role in cell signalling 
(Kowalska et al., 2016). In endothelial cells, Cav-1 par-
ticipates in the regulation of eNOS signalling via modu-
lation of eNOS activation. Cav-1 expression is positively 
correlated with atherosclerosis and obesity (Singh et al., 
2011); it has been reported to modulate MMP-2 activity 
in heart tissue (Chow et al., 2007) and influence AAA 
formation through its functional relationship with an-
giotensin II (Ang II) receptors (Kowalska et al., 2016; 
Takayanagi et al., 2014). It might also act as an immu-
nomodulatory agent via its action on NF-κB and TLR4 
(Mirza et al., 2010), and may influence the effect of sim-
vastatin (Almansob et al., 2012): simvastatin has been 
found to potentially downregulate Cav-1 expression and 
increase eNOS expression in the abdominal aorta of ani-
mals (Arora et al., 2012). Nevertheless, it is not known 
whether statins might cause a similar effect in AAA pa-
tients.
The aim of the study presented here was to determine 
whether simvastatin treatment changes the Cav-1/eNOS 
ratio in tissues of AAA patients. To verify the mecha-
nism behind those changes, measurements were taken 
of the tissue levels of pro-inflammatory IL-6 and IL-17 
and of anti-inflammatory IL-10, as well as the TLR4 re-
ceptor, which are known to regulate Cav-1 expression 
(Jones et al., 2001; Weiss et al., 2015). 
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MATERIALS AND METHODS
Patients. This study comprised 120 patients who un-
derwent open AAA repair between September 2009 and 
December 2012 at the Department of Surgery, Medical 
University of Vienna, as previously described (Piechota-
Polanczyk et al., 2015a).
From that cohort, a group was formed of patients 
treated with simvastatin or who had taken no statins for 
at least six months before the AAA repair procedure. 
The patients were then matched according to the AAA 
diameter. Finally, 12 “non-statin” patients and 24 simv-
astatin-treated patients were chosen to study the effects 
of simvastatin on Cav-1 and eNOS in AAA. 
The following patients were excluded: those who had 
taken statins other than simvastatin; those who had tak-
en non-steroidal anti-inflammatory drugs, except aspirin, 
in the medication list; those with chronic diseases such 
as liver diseases, inflammatory diseases or malignant dis-
eases; those who were recreational drug users; those who 
were abusing alcohol. 
Patient data was prospectively collected after obtaining 
written informed consent, and aneurysm wall tissue was 
harvested during surgery for retrospective analysis. Pa-
tients were matched in a two (simvastatin) to one (non-
statin) ratio by age, sex, and AAA diameter (in the listed 
order). Twelve non-statin patients (10 men, two women) 
were included in the control group, and 24 patients who 
had received simvastatin (22 men, two women) in their 
medical history (20–40 mg daily for a minimum of six 
months) were included to the simvastatin group. AAA 
diameter was measured with pre-operative computed to-
mography angiography.
The study was approved by the local institutional eth-
ics committee (EC 294/2009) at the Medical University 
of Vienna.
Tissue harvesting. The AAA samples were collected 
as described previously (Piechota-Polanczyk et al., 2013). 
After collection, the samples were immediately frozen in 
liquid nitrogen and stored at –80°C.
Enzyme-linked Immunosorbent Assays (ELISA) 
for eNOS, IL-6, IL-10, IL-17. First, 30 mg samples of 
frozen aortic wall were grinded and subjected to protein 
extraction with the Mammalian Cell Lysis Kit accord-
ing to the manufacturer’s instructions (Sigma-Aldrich, 
USA). Following this, ELISA kits were used to assay the 
eNOS, IL-10, IL-17 (R&D Systems, USA) and IL-6 (eBi-
oscience, USA) content, according to the manufacturer’s 
instructions. The samples were diluted where necessary. 
Absorbance was read at 450 nm (VICTOR3 1420, Per-
kin Elmer, USA). All assays were performed in duplicate.
Real-time quantitative polymerase chain reaction 
(RT-qPCR) for Cav-1, eNOS, TLR4. As with the pro-
tein analysis, 30 mg of frozen aortic wall was used for 
RNA extraction with RNeasy Mini Kit (Qiagen, Germa-
ny) according to the manufacturer’s instructions. cDNA 
was synthesized using a High-Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific, USA). RT-
qPCR was conducted on an Applied Biosystems® 7500 
Real-Time PCR Systems (Thermo Fisher Scientific) us-
ing a Power SYBR® Green PCR Master Mix according 
to the manufacturer’s instructions (Thermo Fisher Sci-
entific). Primers were designed using Primer3 version 
0.4.0 software (http://frodo.wi.mit.edu/). hEF-2: Sense 
primer: 5’GAGATCCAGTGTCCAGAGCAG3’, An-
tisense primer: 5’CTCGTTGACGGGCAGATAGG3’; 
Cav-1: Sense primer: 5’AGTGCATCAGCCGTGTC-
TATTCCA3’, Antisense primer: 5’TCTGCAAGTT-
GATGCGGACATTGC3’; TLR4: Sense primer: 5’CA-
GAGTTTCCTGCAATGGATCA3’, Antisense primer: 
5’GCTTATCTGAAGGTGTTGCACAT3’; eNOS: Sense 
primer: 5’CCCGCTTCCTGTTTCTTAGT3’, Antisense 
primer: 5’GGCACAGTCCCTTATGGTAAA3’. Eukary-
otic translation elongation factor 2 (hEF-2) was used as 
a reference gene for analysis. qPCR data was analyzed 
according to the Roche algorithm (Pfaffl et al., 2002). In 
order to avoid the detection of non-specific products 
for each reaction, melting curve analysis was performed. 
The relative expression of Cav-1, TLR4 and eNOS was 
expressed as a ratio of the gene of interest to a refer-
ence gene for each sample. All experiments were run in 
triplicate.
Western blot for Cav-1, eNOS, TLR4. A 30 μg 
sample of protein was separated electrophoretically and 
transferred onto polyvinylidene fluoride membranes 
(PVDF) by wet transfer (Bio-Rad Laboratories, USA). 
Membranes were then blocked in 5% fat-free milk for 
one hour prior to an overnight incubation at 4°C with 
a primary rabbit anti-Cav-1 polyclonal antibody, rabbit 
anti-NOS3 polyclonal antibody and goat anti-TLR4 poly-
clonal antibody (dilution 1:200; Santa Cruz, respectively) 
diluted in 1% fat-free milk. Mouse anti- GAPDH mono-
clonal antibody was used as a reference (dilution 1:1 000; 
Santa Cruz). 
Next, the membranes were washed three times for 
15 minutes with Tris-buffered saline-Tween 20 (TBST) 
buffer, and incubated for one hour with second-
ary antibodies conjugated with alkaline phosphatase: 
anti-rabbit IgG, anti-mouse IgG, anti-goat IgG (dilu-
tions 1:15 000; Sigma-Aldrich). The membranes were 
washed three times in TBST buffer, and the bands 
visualized using Novex®AP Chromogenic Substrate 
(Thermo Fisher Scientific). A densitometric analysis 
of protein expression levels was then conducted using 
ImageJ version 1.34 software (http://rsbinfo.nih.gov/
ij/; USA). The results were calculated as the ratio of 
Cav-1, TLR4 and eNOS expression to the GAPDH 
expression. All experiments were conducted in tripli-
cate for all patients.
Statistical analysis. Continuous demographic and 
biochemical data is presented as median, minimum and 
maximum, or mean ± S.E.M. demographic categorical 
data was described with absolute frequencies and per-
centages. Comparisons between groups were performed 
using the Kruskal-Wallis test (or non-parametric Mann-
Whitney U-test) and χ2 test depending on the normal-
ity of distribution. Two-way analysis of variance and the 
Dunns post hoc test were used to calculate differences. To 
calculate correlations, Spearman’s rank correlation co-
efficient (r) test was used. Grubbs’ test was performed 
to identify statistically significant outliers (p<0.05), and 
these were excluded from the statistical analysis of the 
results (GraphPad Prism software). 
RESULTS
Patients’ characteristics
The non-statin and simvastatin patient data is pre-
sented in Table 1. The median aneurysm diameter 
was 56 mm (49–65 mm) in the non-statin group and 
55.5 mm (48–120 mm) in the simvastatin group. The 
patients receiving statins had significantly lower to-
tal cholesterol (p=0.026) and LDL cholesterol levels 
(p=0.012). No differences in C-reactive protein (CRP), 
fibrinogen, creatinine, haemoglobin, or leukocyte levels 
were noticed (all p≥0.05).
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Simvastatin decreases Cav-1 expression and dose-
dependently increases eNOS in AAA wall
eNOS and CAV-1 expression was evaluated on the 
protein and mRNA level. As Cav-1 is present at high 
levels in most of the cells, Western blot was sufficient to 
evaluate its level. 
Our results indicated that simvastatin treatment 
modulates Cav-1 expression at the gene and protein 
level in the AAA wall (Fig. 1). After simvastatin treat-
ment,  expression of the Cav-1 gene and protein was 
approximately half that (45%) of the non-treated group 
(p=0.033, Fig. 1). Additionally, a daily dose of 20 mg 
simvastatin significantly decreased Cav-1 protein expres-
sion (p<0.05) when compared to controls; however, no 
dose-dependent effect was visible. 
In the caveolae, Cav-1 blocks the action of eNOS by 
binding to it. A decrease in Cav-1 was accompanied by a 
significant increase in eNOS: p<0.01 and p<0.001 for 20 
mg and 40 mg of simvastatin, respectively (Fig. 2B). No 
significant change in eNOS expression was observed at 
the gene level (Fig. 2A). 
A statistically significant correlation was observed be-
tween the expression of Cav-1 and eNOS in simvastatin-
treated patients (p=0.042, Table 2) No other correlation 
between Cav-1, eNOS and cytokines was observed.
Simvastatin’s influence on Cav-1 and eNOS is not 
associated with changed cytokine levels in AAA wall
To confirm whether a decrease in Cav-1 and an in-
crease in eNOS is associated with changes in the pro- 
or anti-inflammatory cytokine profiles, the levels of IL-
6, IL-17 and IL-10 were analyzed (Fig. 3). Lower levels 
of IL-6 tended to be observed in patients with higher 
doses of simvastatin (40 mg), although this relationship 
was not significant (448.3±72.37 pg/ml in control vs. 
293.8±120.7 pg/ml in simvastatin, p=0.055) (Fig. 3A). 
Likewise, there was a tendency towards a lower IL-17 
content following simvastatin treatment (37% reduction): 
60.21±16.12 pg/ml in controls vs. 38.31±7.624 pg/ml in 
the simvastatin group (Fig. 3B). In addition, the simvas-
tatin group demonstrated a strong, dose-dependent ten-
dency towards increasing IL-10 levels (Fig. 3C): Simvas-
tatin at a dose of 40 mg reduced the IL-10 level by 40% 
when compared to controls (p=0.055). 
Simvastatin treatment does not influence TLR4 
expression in the AAA wall
Changes in Cav-1 are known to be associated with 
TLR4 stimulation (Wang et al., 2009). Therefore, in this 
Table 1. Patient characteristics. 
Patient characteristics are presented in the table. Data is presented as frequencies or median (minimum-maximum). Statistical significance 
for binary variables was assessed using generalized linear models, while metric values were analysed using linear mixed regression mod-
els. P-value p<0.05 was considered as statistically significant and is indicated in bold.
Non-statin
(n=12)
Simvastatin
(n=24) P value
Age (range) 69 (50–75) 68 (55–80) 1.000
AAA diameter [mm] (range) 56 (49–65) 55.5 (48–120) 0.710
Body mass index [kg/m2] (range) 27.5 (23–37) 26.0 (22.0–34.5) 0.282
Coronary artery disease 4/12 (33%) 5/24 (21%) 0.815
Cerebrovascular artery disease 8/12 (67%) 8/24 (33%) 0.239
Hypertension 10/12 (83%) 21/24 (87%) 0.867
Nicotine 8/12 (67%) 16/24 (67%) 0.780
CRP [mg/dl] median (range) 0.35 (0.03–3.0) 0.33 (0.06–3.28) 0.804
Cholesterol [mg/ml] median  (range) 236.5 (143.0–267.0)
192.5 
(110.0–264.0) 0.026
HDL [mg/ml] median  (range) 46.0 (32.0–59.0) 47.0 (29.0–75.0) 0.679
LDL [mg/dl] median (range) 141.7 (79.2–181.0)
110.0 
(56.0–169.0) 0.012
Creatinin  [mg/dl] median (range) 1.15 (0.76–1.48) 1.1 (0.78–4.0) 0.703
Haemoglobin [g/dl] median  (range) 14.0 (13.0–15.7) 13.6 (12.4–18.0) 1.000
Leucocytes [mln/ml] median (range) 8.0 (6.0–11.0) 7.2 (5.3–13.0) 0.251
Fibrinogen [mg/dl] median  (range) 391.0 (260.0–549.0)
347.0 
(213.0–581.0) 0.136
Table 2. Correlations of Cav-1, eNOS and cytokines in the simv-
astatin study group.
The correlation of the expression of Cav-1 assessed by Western 
blot, eNOS expression assessed by ELISA, Cav-1 and eNOS gene 
expression assessed by RT-qPCR and cytokine level assessed by 
ELISA, were made with Spearman’s correlation test calculated for 
the study group (simvastatin). P<0.05 was considered as statistical-
ly significant and is marked in bold, vs., versus, Rs-Spearman rank 
correlation coefficient.
Rs P value
Cav-1 vs. eNOS –0.1544 0.4583
IL-6 vs. eNOS –0.09 0.6688
IL-10 vs. eNOS 0.09652 0.6537
IL-17 vs. eNOS –0.04162 0.8434
Cav-1 vs. eNOS 0.2243 0.3035
IL-6 vs. Cav-1 –0.1157 0.5905
IL-10 vs. Cav-1 0.1937 0.3759
IL-17 vs. Cav-1 0.1726 0.4199
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study we examined whether simvastatin treatment in-
fluences the observed changes in Cav-1 and eNOS by 
influencing the TLR4 expression. However, simvastatin 
was not found to have any significant effect on TLR4 
(Fig. 4). 
DISCUSSION
Our study demonstrates that simvastatin treatment de-
creases Cav-1 level but significantly increases eNOS ex-
pression in patients with AAA. At rest, eNOS is inactive 
and anchored to the caveolae by Cav-1. A recent study 
found an elevated Cav-1 gene and protein expression to 
be associated with impaired eNOS activity in cardiovas-
cular diseases (Ricchiuti et al., 2011). In addition, Cav-1 
and eNOS gene polymorphisms have been identified in 
patients with arterial diseases, suggesting that these genes 
play a role in the development of intima thickness (Testa 
et al., 2012). Cav-1 was also proposed to play a critical role 
in a mouse model of AAA formation, as Cav-1 knockout 
mice did not develop Ang II-induced AAA (Takayanagi et 
al., 2014); the authors suggest that Cav-1 may induce an 
increase in the level of  the ADAM17 metalloprotease, 
which further activates TNF-α and epithelial growth fac-
tor receptor, leading to AAA development (Takayanagi 
et al., 2014). 
In addition, a decrease in Cav-1 and an increase in 
eNOS has been reported in endothelial tissue rather than 
in smooth muscle cells in rabbits on a high-fat diet fol-
lowing simvastatin treatment (Arora et al., 2012); how-
ever, no change in eNOS phosphorylation was detect-
ed, suggesting a possible role might be played by other 
mechanisms related to the antioxidative role of statins or 
accumulation of cGMP, which is an indicator of eNOS-
dependant NO bioavailability (Meda et al., 2010; Piecho-
ta-Polanczyk et al., 2012).
Our findings indicate that simvastatin has a dose-de-
pendent influence on eNOS but not on Cav-1. Patients 
treated with 40 mg of simvastatin demonstrated a sig-
nificantly higher eNOS protein expression than those 
Figure 1. Simvastatin influence on the Cav-1 gene (A) and protein (B) expression. 
The results from representative Western blots are presented in panel (C). Gene expression was evaluated with RT-qPCR, whereas protein 
expression was evaluated by the Western blot technique. Results are presented as mean ± S.E. *p<0.05; Cav-1, caveolin-1; EF-2, elonga-
tion factor 2; O.D., optical density.
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treated with 20 mg. Previous studies have also found 
statins to have a similar effect on endothelial cells, where 
simvastatin induced eNOS phosphorylation in a dose-
dependent manner, leading to further activation of Akt 
and AMPK (Hou et al., 2015). Those two intracellular 
proteins regulate eNOS activity (Ching et al., 2011; Sun 
et al., 2006).
However, the lack of dose dependence observed in 
our study for Cav-1 may be partially associated with the 
low number of patients treated with 40 mg of simvasta-
tin, as a partial trend was visible. Nonetheless, it should 
be stated that the effect of statins strongly depends on 
the cell type and the type of statin used. For example, 
simvastatin at a dose of 10 µM increases eNOS and 
[NO]/[NOO–] balance in human umbilical endothe-
lial cells to the same extent as atorvastatin used at half 
of that dose (5 µM) (Heeba et al., 2007). Furthermore, 
statins may have an anti- or pro-oxidative effect de-
pending on their concentration and the type of cells on 
which they are acting (Loboda et al., 2006). The effect 
of simvastatin may also vary depending on the admin-
istered dose. For instance, studies on tumor vasculariza-
tion found mice treated with a low dose of simvastatin 
(0.2 mg/kg) to have augmented eNOS phosphorylation 
when compared to mice treated with a higher dose (10 
mg/kg); however, the higher dose was also associated 
with a significantly lower level of oxidative stress (Chen 
et al., 2013). Therefore, both the type and dose of sta-
tin may influence the results associated with the effect 
of simvastatin on Cav-1 and eNOS obtained in the study 
presented here.
Various factors regulate the changes in Cav-1 and 
eNOS, including cytokines. However, our results indicate 
that simvastatin treatment had no effect on the expres-
sion of pro-inflammatory IL-6, IL-17 or anti-inflamma-
tory IL-10, three cytokines which play a key role in the 
development of AAA (Johnston et al., 2013; Jones et al., 
2001). Despite this, previous studies have found that 
pro-inflammatory cytokines, especially IL-6, are associat-
ed with AAA formation and that lack of Cav-1 decreases 
Figure 2. Simvastatin influence on the eNOS gene (A) and protein (B) expression indicated a dose-dependent increase in eNOS. 
The results from a representative Western blot are presented in panel (C). The result were obtained by RT-qPCR, ELISA and Western blot 
techniques and are presented as mean ± S.E. **p<0.01; ***p<0.001; eNOS, endothelial nitric oxide synthase; EF-2, elongation factor 2; 
O.D., optical density.
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IL-6 level in the vascular media layer (Takayanagi et al., 
2014). In addition, a negative correlation has been ob-
served between Cav-1 and IL-17 in mice with ulcerative 
colitis (Weiss et al., 2015). 
Additionally, the results of clinical trials indicate that 
patients subjected to non-coronary artery cardiac surgery 
demonstrated a reduced inflammatory response follow-
ing perioperative, but not postoperative, treatment with 
simvastatin (20 mg); this was reflected by lower IL-6, 
IL-8 and Cav-1 levels but higher eNOS expression and 
NO production. Increased eNOS levels were associated 
with higher Akt phosphorylation, while decreased Cav-1 
was accompanied by reduced phosphorylation of p38 of 
MAPK in the heart tissue (Almansob et al., 2012). There-
fore, the influence of simvastatin on Cav-1 and eNOS in 
acute inflammatory response in these states may be asso-
ciated with changes in pro-inflammatory cytokine levels.
Finally, we wanted to verify if simvastatin treatment 
may change the TLR4 expression, which has been 
shown to regulate Cav-1 in cells (Wang et al., 2009). 
However, no difference in the TLR4 gene or protein 
expression was observed in the AAA tissue of the ana-
lysed groups. Hence, our results are in line with Azor 
et al. (Azor et al., 2011) who found that simvastatin or 
lovastatin administration had no influence on the TLR4 
level in chronic idiopathic urticaria. In contrast, Mout-
zouri and coworkers (2012) report that a high dose of 
simvastatin (40 mg) or the combination of a low dose 
of simvastatin/ezetimibe (10/10 mg) reduces TLR2 and 
TLR4 membrane expression in patients with hypercho-
lesterolemia treated with lipopolysaccharide (LPS). Also, 
at a dose of 80 mg/day for four days, simvastatin re-
duced the influence of LPS-induced elevated TLR2 and 
TLR4 level on circulating monocytes and suppressed 
the activity of TNF-α and monocyte chemoattractant 
protein-1 (Niessner et al., 2006). The protective effect 
of statins on TLR4 receptors may be associated with 
the attenuation of the TLR4/NF-kB-mediated inflam-
Figure 3. Simvastatin influence on IL-6 (A) IL-17 (B) and IL-10 (C) indicated no influence of simvastatin on those cytokines. 
Results are presented as mean ± S.E. in pg/ml after adjustment to protein concentration obtained by ELISA tests. IL, interleukin.
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matory response, as shown for murine models of brain 
injury and lung inflammation (Chen et al., 2009; Shao et 
al., 2007).
To summarise, our findings indicate that patients dis-
played a significantly lower Cav-1 and higher eNOS ex-
pression in AAA tissue following simvastatin treatment. 
Therefore, simvastatin treatment may affect the Cav-1 
and Cav-1/eNOS ratio in the AAA wall, suggesting that 
statins may play a potentially beneficial role in AAA pa-
tients. Nevertheless, further studies are necessary to veri-
fy the exact mechanisms behind those observations.
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